FinnCap reiterated their corporate rating on shares of Allergy Therapeutics (LON:AGY) in a research report report published on Thursday, ThisIsMoney.Co.Uk reports.
Separately, Numis Securities reaffirmed a buy rating and issued a GBX 35 ($0.46) target price on shares of Allergy Therapeutics in a research note on Monday, March 18th.
Shares of AGY opened at GBX 13.25 ($0.17) on Thursday. The company has a 50 day moving average of GBX 13.69. The stock has a market capitalization of $84.29 million and a P/E ratio of -26.50. The company has a debt-to-equity ratio of 6.20, a current ratio of 3.74 and a quick ratio of 3.08. Allergy Therapeutics has a 1-year low of GBX 8 ($0.10) and a 1-year high of GBX 28.95 ($0.38).
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.